The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

--Lexeo Therapeutics, Inc., a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV ...

AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the ...

By making cell therapies predictively, scalable, and accessible, CellVoyant’s vision is to enable the cell therapy industry to deliver its full-fledged promise and, quite simply, revolutionize ...

Potency assays are a regulatory linchpin in cell and gene therapy (CGT) development, but their design and validation remain a persistent and often underestimated challenge for therapy developers ...

The indication count follows the same criteria as used in Fig. 1. b, Target analysis of somatic cell therapies. c, Target analysis of gene therapies.